On December 7, 2022, the Federal Trade Commission (“FTC”), along with the U.S. Department of Health and Human Services (“HHS”) and the U.S. Food and Drug Administration (“FDA”), announced updates to the Mobile Health App Interactive Tool—a questionnaire designed to help mobile health app developers identify federal laws and
Continue Reading FTC, HHS, and FDA Update Tool to Help Mobile Health App Developers Understand Legal RequirementsMobile Apps
OIG Issues Advisory Opinion on Digital Program for the Treatment of Substance Use Disorders
By Rujul Desai & Beth Braiterman on
On March 2, 2022, the Office of Inspector General (“OIG”) for the Department of Health and Human Services (“HHS”) posted an advisory opinion concluding that a digital program for the treatment of substance use disorders would raise minimal fraud and abuse risk. OIG advisory opinions address the application of certain…
Continue Reading OIG Issues Advisory Opinion on Digital Program for the Treatment of Substance Use Disorders
Germany Publishes Draft Regulation on the Reimbursement of Digital Health Applications
Germany recently enacted a law that enables state health insurance schemes to reimburse costs related to the use of digital health applications (“health apps”), but the law requires the Federal Ministry of Health to first develop the reimbursement process for such apps. Accordingly, on January 15, 2020, the German government…
Continue Reading Germany Publishes Draft Regulation on the Reimbursement of Digital Health Applications
Pharmaceutical Digital Health Innovators Take Note: FDA Public Hearing on an Innovative Approach to Devices Referencing Drugs
By Wade Ackerman on
On November 16, 2017, the Food and Drug Administration (“FDA” or the “Agency”) will hold a public hearing on a proposed approach for sponsors seeking to market devices referencing drugs (“DRDs”) when the drug sponsor does not wish to collaborate with the sponsor of the device. FDA will accept comments to the docket until January 15, 2018.
Continue Reading Pharmaceutical Digital Health Innovators Take Note: FDA Public Hearing on an Innovative Approach to Devices Referencing Drugs